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1. INTRODUCTION {#mgg31034-sec-0005}
===============

CHARGE syndrome, a rare autosomal dominant syndrome, has been estimated to occur in 1:10,000 newborns in the world (Jongmans et al., [2006](#mgg31034-bib-0019){ref-type="ref"}). The disorder is characterized by major clinical manifestations including ocular coloboma, congenital heart defects, choanal atresia, retardation of growth, genital hypoplasia and ear abnormalities and additional less frequent clinical anomalies such as cleft lip/palate, facial asymmetry (a broad forehead and prominent nasal bridge), esophageal anomalies, feeding difficulties, cranial nerve dysfunction, defects in neural crest migration, hypothalamo‐hypophyseal dysfunction, agenesis of the semicircular canals, limb deformity, developmental delay and hyperactive behavior (Blake et al., [1998](#mgg31034-bib-0004){ref-type="ref"}; Blake & Prasad, [2006](#mgg31034-bib-0005){ref-type="ref"}; Graham, Beth, Rosner, Dykens, & Visootsak, [2005](#mgg31034-bib-0014){ref-type="ref"}; Issekutz, Graham, Graham, Prasad, Smith, & Blake, [2005](#mgg31034-bib-0018){ref-type="ref"}; Lalani, Hefner, Hefner, Belmont, & Davenport, [2012](#mgg31034-bib-0022){ref-type="ref"}; Lanson, Green, Green, Roland, Lalwani, & Waltzman, [2007](#mgg31034-bib-0025){ref-type="ref"}; Okuno et al., [2017](#mgg31034-bib-0033){ref-type="ref"}; Song et al., [2011](#mgg31034-bib-0038){ref-type="ref"}; Tellier et al., [1998](#mgg31034-bib-0040){ref-type="ref"}).

The mutation in the chromodomain helicase DNA binding protein 7 (*CHD7*) (located on chromosome 8q12.1) gene was the most common in patients with CHARGE syndrome. It is estimated that 15% missense mutations, 10% splice site mutations, 5% chromosomal and exonic deletions and chromosomal rearrangements are found in the *CHD7* gene variants in CHARGE syndrome (Zentner, Layman, Layman, Martin, & Scacheri, [2010](#mgg31034-bib-0044){ref-type="ref"}). In addition, the novel monoallelic frameshift mutation of *CHD7* (c.4656dupT), de novo variant in exon 37 of *CHD7* (c.8016G\>A) and intronic mutations of *CHD7* (c.5405‐7G\>A, c.5405‐17G\>A, c.5405‐13G\>A and c.5405‐18C\>A) are also found in patients with CHARGE syndrome (Legendre et al., [2018](#mgg31034-bib-0026){ref-type="ref"}; Ungaro et al., [2018](#mgg31034-bib-0042){ref-type="ref"}; Xu, Shi, Shi, & Zhu, [2018](#mgg31034-bib-0043){ref-type="ref"}). Besides common *CHD7* gene variants, the mutations of elongation factor Tu GTP binding domain containing 2 (*EFTUD2*), lysine methyltransferase 2D (*KMT2D*), semaphorin 3E (*SEMA3E*) (OMIM**\#** 214800) and arginine‐glutamic acid dipeptide repeats (*RERE*) duplication could also cause CHARGE syndrome (Badalato et al., [2017](#mgg31034-bib-0001){ref-type="ref"}; Jordan et al., [2018](#mgg31034-bib-0020){ref-type="ref"}; Lehalle et al., [2014](#mgg31034-bib-0027){ref-type="ref"}; Luquetti et al., [2013](#mgg31034-bib-0029){ref-type="ref"}; Sanlaville & Verloes, [2007](#mgg31034-bib-0036){ref-type="ref"}).

It is noted that the various anomalies in CHARGE syndrome could be life‐threatening and approximately 30% of affected children die before 5 years of age (Zentner et al., [2010](#mgg31034-bib-0044){ref-type="ref"}). Survival of those affected children is tightly associated with age (Hale, Niederriter, Niederriter, Green, & Martin, [2016](#mgg31034-bib-0016){ref-type="ref"}; Hsu et al., [2014](#mgg31034-bib-0017){ref-type="ref"}). As CHARGE syndrome significantly resembles other patterns of anomalies, genetic testing such as mutation screening of potential candidate genes should be emphasized as a useful method in clinical diagnosis. It is worth mentioning that whole exome sequencing is a valuable tool to explore the genetic basis of diseases (Bamshad et al., [2011](#mgg31034-bib-0002){ref-type="ref"}), which may be helpful in clinical diagnosis. In this study, we investigated an labor induced fetus with CHARGE syndrome. Using whole exome sequencing, we identified a novel heterozygous missense mutation (c.1327G\>A; p. Ala443Thr) in *SEMA3E*, which may be another causative mutation of CHARGE syndrome. Our results may provide a new genetic basis for understanding the pathology mechanism of CHARGE syndrome.

2. MATERIAL AND METHODS {#mgg31034-sec-0006}
=======================

2.1. Ethical compliance {#mgg31034-sec-0007}
-----------------------

Our study was approved by the ethics committee of the local hospital.

2.2. Sample collection {#mgg31034-sec-0008}
----------------------

In this study, a pregnant woman (29 years old) with G1P0 was recruited. According to the diagnosis criteria, the fetus was diagnosed with CHARGE syndrome on prenatal examination of the pregnant woman. The pregnant woman was normal and had no family history or history of adverse contact. Moreover, prenatal pregnancy examination was performed during the pregnancy. In addition, her husband also had a normal phenotype. In order to explore the pathogenesis of CHARGE syndrome, the pregnancy was terminated. Whole exome sequencing of the fetal thigh muscle tissue and peripheral blood (2 ml) of his parents was performed.

2.3. Exome sequencing {#mgg31034-sec-0009}
---------------------

Genomic DNA from the fetal thigh muscle tissue of and peripheral blood of his parents was extracted using DNeasy Blood & Tissue Kit (DP348) (Qiagen). DNA content and quality was determined using Nanodrop and agarose gel electrophoresis, respectively. Genomic DNA was broken into random fragments and purified. The Roche SeqCap EZ MedExome Kit was used to capture genome‐wide exons. After enrichment of quality control, the captured fragments were used for genomic library preparation. An IIIumina Hiseq XTen sequencer was used for double side high flux PE150 sequencing. The average sequencing depth is 100× and more than 95% of the area reached more than 20× of the coverage. The original sequencing data were presented in FASTQ format. After basic data analysis including image recognition, filtering connection sequences and decontamination), the data were processed as follows: (a) Using Burrows‐Wheeler Alignment (BWA) (<http://bio-bwa.sourceforge.net/bwa.shtml>) BWA software (version 0.7‐6a), short reads and the reference genome (hg19) (<http://hgdownload.soe.ucsc.edu/goldenPath/hg19/bigZips/)(NG_021242.2>) were compared to determine the position of short sequences in the genome; (b) The SAMtools software (version 0.1.18) was used to classify and convert the short sequences; (c) Picard (<http://picard.sourceforge.net/>) software (version 1.91) was utilized to remove redundant information and noise generated during sequencing; (d) The sites (SNV and InDel) in sequencing data were obtained by Genome Analysis Toolkit (GATK) software (version 2.6‐4) (McKenna et al., [2010](#mgg31034-bib-0030){ref-type="ref"}); (e) The functional annotation of these mutation sites were formed by Annovar software (version 2013 August 23).

2.4. Bioinformatics analysis {#mgg31034-sec-0010}
----------------------------

All mutations were filtered by ExAC, 1000 Genomes Project and ESP6500 ordinary public database. According to the variation in genes corresponding to genetic pattern of the disease, the variation could be classified as autosomal dominant, autosomal recessive, X‐linked dominant and X‐linked recessive. For autosomal dominant or X‐linked dominant mutation loci, variation with frequencyless than 0.01 in the database was reserved; for the autosomal recessive or X‐linked recessive mutation loci, variation with a frequency less than 0.05 in the database was reserved. After removing the synonymous mutation loci, the remaining variation loci within 20bp of exons were sorted by combining the harmful score predicted by SIFT, polyphen2 and other software. The possible pathogenic mutation loci were screened out according to the disease phenotype and family information.

2.5. In silico analysis {#mgg31034-sec-0011}
-----------------------

Multiple alignments of protein sequences in different species was analyzed based on the tool (<https://www.ncbi.nlm.nih.gov/tools/cobalt/cobalt.cgi?LINK_LOC=BlastHomeLink>). The protein conserved domains were further identified using the Conserved Domain Search Service (<http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi>).

2.6. Mutation validation and cosegregation analysis {#mgg31034-sec-0012}
---------------------------------------------------

In order to validate potential causative variants in the fetus and his parents, Sanger sequencing was carried out using a ABI 3730xl sequencer (Applied Biosys terms company). In addition, segregation analysis was performed for all family members. The interpretation and evidence grading of genetic variation was performed according to the latest editor of the American society for medical genetics and genomics (ACMG) standard and guidelines. Primer pairs used to amplify fragments encompassing individual variants were designed by Primer 5.

3. RESULTS {#mgg31034-sec-0013}
==========

3.1. Clinical feature of fetus {#mgg31034-sec-0014}
------------------------------

In the color ultrasonography in early pregnancy, reverse reflux of venous catheter of the fetus was observed (Figure [1](#mgg31034-fig-0001){ref-type="fig"}a). In the ultrasonography in prenatal diagnosis in the second trimester, a cystic dark area was observed in both choroid plexuses of the fetus (Figure [1](#mgg31034-fig-0001){ref-type="fig"}b), and the larger dark area was about 0.7 × 0.4 cm. The left ulna was visible, and the radius was short measuring about 0.35 cm (Figure [1](#mgg31034-fig-0001){ref-type="fig"}c). The right ulna was visible, the radius was not shown (Figure [1](#mgg31034-fig-0001){ref-type="fig"}d), and the hands were hooked (Figure [1](#mgg31034-fig-0001){ref-type="fig"}e). During the examination, the left foot was in the same plane with the left tibiofibula bone, the heart was located in the right thoracic cavity, the apex of the heart was toward the right, the atrial septum and the upper ventricular septum were not detected, and only one set of atrioventricular valves was observed. No vertebral bones in the left side of the fetal spine were observed (Figure [1](#mgg31034-fig-0001){ref-type="fig"}f). In the second color ultrasound examination of the fetus, mirror right ventricular (Figure [1](#mgg31034-fig-0001){ref-type="fig"}g) with an atrioventricular septal defect (Figure [1](#mgg31034-fig-0001){ref-type="fig"}h) was observed. Bilateral radial dysplasia, left foot pronation posture (Figure [1](#mgg31034-fig-0001){ref-type="fig"}i), left coccyx dysplasia, and bilateral choroid plexus cysts were observed. The above clinical feature of the fetus was in line with the diagnostic criteria of CHARGE syndrome.

![Color ultrasonography of the fetus. (a) Color ultrasonography of the fetus in early pregnancy; the reverse reflux of venous catheter of the fetus; (b--i) Color ultrasonography of the fetus in the second trimester. (b) A cystic dark area was observed in both choroid plexuses of the fetus; (c) the left ulna and radius were visible; (d) the right ulna was visible; (e) the hands were curving; (f) the left foot and the heart were observed; (g) mirror right ventricular was observed; (h) an atrioventricular septal defect was observed; (i) bilateral radial dysplasia and left foot pronation posture was observed](MGG3-8-e1034-g001){#mgg31034-fig-0001}

3.2. Genetic and bioinformatics analysis {#mgg31034-sec-0015}
----------------------------------------

In this study, we did not find any other known gene mutations for CHARGE syndrome, such as *CHD7* in the genome of the fetus. Interestingly, a heterozygous missense mutation of *SEMA3E* (c.1327G\>A; p. Ala443Thr) was found in the fetus. However, the mutation was not detected at this locus in either parent, suggesting that the mutation was a new mutation in the fetus. The mutation frequency was not found in the ExAC, 1000 Genomes Project and ESP6500 ordinary public database, indicating the rarity of the mutation. In addition, predictive soft PROVEAN/SIFT, Polyphen2 and FATHMM indicated that the mutation was harmful and destructive to protein function (Figure [2](#mgg31034-fig-0002){ref-type="fig"}).

![The harmful prediction of the mutation of *SEMA3E* by software of PROVEAN/SIFT (a), Polyphen2 (b) and FATHMM (c)](MGG3-8-e1034-g002){#mgg31034-fig-0002}

3.3. In silico analysis {#mgg31034-sec-0016}
-----------------------

The c.1327G\>A mutation in *SEMA3E* resulted in p. Ala443Thr change. Moreover, the multiple alignment of protein sequences and protein conserved domains analysis showed that the amino acid in 443 locus of SEMA3E protein sequence was located in the domain of Sema superfamily (Figure [3](#mgg31034-fig-0003){ref-type="fig"}a), and it was highly conserved across species of human, rhesus, rat, dog, elephant, *Xenopus laevis* and zebra fish (Figure [3](#mgg31034-fig-0003){ref-type="fig"}b).

![(a) The affected amino acid residue was highly conserved across species. (b) Conserved domains in SEMA3E protein. Arrow represents the mutation site](MGG3-8-e1034-g003){#mgg31034-fig-0003}

3.4. Sanger sequencing {#mgg31034-sec-0017}
----------------------

In order to further validate the heterozygous missense variants of c.1327G\>A mutation in *SEMA3E*, Sanger sequencing was performed. The results showed that the c.1327G\>A mutation in *SEMA3E* was found in the fetus (Figure [4](#mgg31034-fig-0004){ref-type="fig"}a). However, the mutation was not found in his parents (Figure [4](#mgg31034-fig-0004){ref-type="fig"}b). The Sanger validation result was consistent with the WES analysis.

![Sanger validation results of *SEMA3E* variants in the fetus (a) and his parents (b). Arrow represents the mutation site.](MGG3-8-e1034-g004){#mgg31034-fig-0004}

4. DISCUSSION {#mgg31034-sec-0018}
=============

Although most patients carry *CHD7* gene mutations, some other genes are also associated with CHARGE syndrome. It was shown that (semaphorin) 3E (*SEMA3E*) was interrupted by a de novo balanced translocation \[t(2;7)(p14;q21.11)\] in a CHARGE syndrome patient (Lalani et al., [2004](#mgg31034-bib-0023){ref-type="ref"}). In this study, we first found a heterozygous missense mutation (c.1327G\>A; p. Ala443Thr) in the gene of *SEMA3E* in labor induced fetus with CHARGE syndrome, which may be another potential causative gene mutation of *SEMA3E* for CHARGE syndrome. In addition, we also validated the mutation in the fetus and his parents using Sanger sequencing, which showed that the *SEMA3E* (c.1327G\>A; p. Ala443Thr) mutation was cosegregated between the fetus and his parents. Our result indicated that the novel mutation of *SEMA3E* may be valuable in illustrating the pathological mechanism of CHARGE syndrome.

*SEMA3E*, contains 13 conserved cysteine residues and three potential A'‐glycosylation sites, was first identified in metastatic cell lines (Christensen et al., [1998](#mgg31034-bib-0008){ref-type="ref"}). The expression of *SEMA3E* was found in the eye (retina), nervous system and bone (osteoclasts/osteobalsts) and lung tissues (Christensen et al., [1998](#mgg31034-bib-0008){ref-type="ref"}; Ryynänen et al., [2017](#mgg31034-bib-0034){ref-type="ref"}; Sun et al., [2017](#mgg31034-bib-0039){ref-type="ref"}). Several reports have demonstrated the role of *SEMA3E* in angiogenesis. It is reported that *SEMA3E* plays a crucial role in vascular patterning, such as formation of the first embryonic blood vessel (Gu et al., [2005](#mgg31034-bib-0015){ref-type="ref"}; Meadows et al., [2012](#mgg31034-bib-0031){ref-type="ref"}). Gitler, Lu, Lu, & Epstein, [2004](#mgg31034-bib-0013){ref-type="ref"} and Gu et al., [2005](#mgg31034-bib-0015){ref-type="ref"} found that *SEMA3E* is required in the angiogenesis remodeling of specific vessel subtypes. In specific vascular beds, *SEMA3E* can trigger repulsion of endothelial cells (Gu et al., [2005](#mgg31034-bib-0015){ref-type="ref"}; Kim, Oh, Oh, Gaiano, Yoshida, & Gu, [2011](#mgg31034-bib-0021){ref-type="ref"}). Furthermore, *SEMA3E* promotes the antiangiogenic effect in endothelial cells by inhibiting R‐Ras and disassembling adhesive structures involving integrins (Sakurai et al., [2010](#mgg31034-bib-0035){ref-type="ref"}). The inhibitory/repulsive signaling between *SEMA3E* and *PLEXD1* is found in the retina vasculature (Oh & Gu, [2013](#mgg31034-bib-0032){ref-type="ref"}). In this study, some abnormalities in angiogenesis were also found, such as the reverse reflux of venous catheter of the fetus. It is suggested that *SEMA3E* may be an important regulator in angiogenesis.

*SEMA3E* is also involved in the development of central nervous system. *SEMA3E* plays a key role in regulating synaptic connectivity and axonal growth in the central nervous system (Bellon et al., [2010](#mgg31034-bib-0003){ref-type="ref"}; Chauvet et al., [2007](#mgg31034-bib-0007){ref-type="ref"}; Ding, Oh, & Oh, [2011](#mgg31034-bib-0011){ref-type="ref"}). Exposure of developing hippocampus subicular neurons to *SEMA3E* could promote axonal growth in mouse (Bellon et al., [2010](#mgg31034-bib-0003){ref-type="ref"}). In addition, it has been indicated that *SEMA3E* can promote the survival of the maturing hypothalamus (Cariboni et al., [2015](#mgg31034-bib-0006){ref-type="ref"}). Interestingly, abnormalities in the nervous systems caused by *SEMA3E* are found in CHARGE patients (Gay, Zygmunt, Zygmunt, & Torres‐Vázquez, [2011](#mgg31034-bib-0012){ref-type="ref"}). In addition, *SEMA3E* is related to idiopathic hypogonadotropic hypogonadism disorders (Topaloglu, [2017](#mgg31034-bib-0041){ref-type="ref"}). In addition, *SEMA3E* also play roles in angiogenesis and central nervous system in lower vertebrate animals, such as zebra fish. Lamont RE et al found that *Sema3e* acted autonomously and nonautonomously in angioblasts to modulate interactions among themselves (Lamont, Lamont, Lamont, & Childs, [2009](#mgg31034-bib-0024){ref-type="ref"}). Moreover, loss of *Sema3e* results in delayed exit of angioblasts from the dorsal aorta in intersegmental vessels formation. Dell AL et al reported that elevated cyclic adenosine monophosphate (cAMP) levels increased the sensitivity of retinal axons to *Sema3e*, and consequently facilitated retinal axon crossing in the chiasm (Dell, Fried‐Cassorla, Fried‐Cassorla, Xu, & Raper, [2013](#mgg31034-bib-0010){ref-type="ref"}). It is noted that *Sema3e* is required for migration of cranial neural crest cells in the pathogenesis of CHARGE syndrome (Liu et al., [2019](#mgg31034-bib-0028){ref-type="ref"}).

In addition, *SEMA3E* is also associated with heart and bone development. Copy number variants of *SEMA3E* are found in patients with heart defects (Silversides et al., [2012](#mgg31034-bib-0037){ref-type="ref"}). *SEMA3E* knockout leads to the cardiovascular abnormalities in patients with CHARGE syndrome (Gay et al., [2011](#mgg31034-bib-0012){ref-type="ref"}). In addition, *SEMA3E* plays a crucial role in regulating bone homeostasis in osteoblasts (Ryynänen et al., [2017](#mgg31034-bib-0034){ref-type="ref"}). In this study, several heart abnormalities including mirror right ventricular and atrioventricular septal defect and bone abnormalities including short radius, curving hands, left foot pronation posture and no visible vertebral bones in the left side of the fetal spine were found. It is indicated that *SEMA3E* may be associated with heart and bone development.

In the molecular genetics level, mutations of *SEMA3E* have been found in CHARGE syndrome. By sequencing, a missense mutation of *SEMA3E* was revealed in 72 patients with CHARGE syndrome (Lalani et al., [2004](#mgg31034-bib-0023){ref-type="ref"}). The de novo missense mutation S703L of *SEMA3E* has also been uncovered in CHARGE syndrome patients (Damien & Alain, [2007](#mgg31034-bib-0009){ref-type="ref"}). In addition, nonsynonymous SNPs including G623C, G603T, C1062T, G1272A, A2149G, A2211G in *SEMA3E* were seen in patients with CHARGE syndrome (Lalani et al., [2004](#mgg31034-bib-0023){ref-type="ref"}). Silversides CK found that *SEMA3E* was involved in regulating the NOTCH pathway in CHARGE syndrome (Silversides et al., [2012](#mgg31034-bib-0037){ref-type="ref"}). In this study, we first found a novel heterozygous missense mutation (c.1327G\>A; p. Ala443Thr) in *SEMA3E* in labor induced fetus with CHARGE syndrome. Moreover, the mutation frequency was not found in the ExAC, 1000 Genomes Project and ESP6500 ordinary public database, indicating the rarity of the mutation. The mutation was highly analogous across species of human, rhesus, rat, dog, elephant, *Xenopus laevis* and zebra fish. In addition, predictive soft PROVEAN/SIFT, Polyphen2 and FATHMM indicated that the mutation was harmful and destructive to protein function. It is indicated that the novel heterozygous missense mutation (c.1327G\>A; p. Ala443Thr) in *SEMA3E* may be another potential causative factor for CHARGE syndrome.

In other words, our findings reported here show that *SEMA3E* (c.1327G\>A; p. Ala443Thr) may be another pathogenic factor for CHARGE syndrome. Our results may be helpful in understanding the potential pathological mechanism of CHARGE syndrome. However, there is a limitation of our study. The underlying signaling pathway mechanism is not investigated, and further animal model or cell culture experiments are needed.
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